With this in mind, and as we clearly outlined in the Discussion section of our article, we intentionally chose middle-aged animals to better relate to the prior work of Rosenzweig et al. (2019), starting the anti-PD-1 antibody treatment when the tauopathy mice have moderate to severe tau pathology. The gene discussed is MAPT; the disease is tauopathy.